Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.967 USD | -0.31% | -46.28% | -73.21% |
May. 30 | Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from S&P TMI Index | CI |
May. 27 | Finch Therapeutics Group, Inc.(OTCPK:FNCH) dropped from NASDAQ Composite Index | CI |
Business Summary
Number of employees: 1
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biological Drugs
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -87.57% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -87.57% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Matthew Blischak
CEO | Chief Executive Officer | - | 23-05-15 |
Lance Thibault
DFI | Director of Finance/CFO | 58 | 23-05-15 |
Sonia Timberlake
CTO | Chief Tech/Sci/R&D Officer | - | - |
Matthew Nelson
PRN | Corporate Officer/Principal | - | 21-06-30 |
Michelle L. Rose
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Graf
CHM | Chairman | 52 | 21-04-22 |
Jeffery Smisek
BRD | Director/Board Member | 69 | 17-08-31 |
Chris Shumway
BRD | Director/Board Member | 58 | 20-08-31 |
Domenic Ferrante
BRD | Director/Board Member | 58 | 19-09-24 |
Christian Lange
BRD | Director/Board Member | 44 | 17-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,605,763 | 746,985 ( 46.52 %) | 0 | 46.52 % |
Company contact information
Finch Therapeutics Group, Inc.
75 State Street Suite 100
02109, Boston
+
http://www.finchtherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
-73.21% | 1.55M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- FNCH Stock
- Company Finch Therapeutics Group, Inc.